Report of the National Heart, Lung, and Blood Institute Workshop on Lipoprotein(a) and Cardiovascular Disease: Recent Advances and Future Directions

Clinical Chemistry

Volumn 49, Issue 11, 2003, Pages 1785-1796

  Marcovina, Santica M ^a   Koschinsky, Marlys L ^b   Albers, John J ^a   Skarlatos, Sonia ^c  

^a UNIVERSITY OF WASHINGTON   (United States)

^b QUEEN S UNIVERSITY   (Canada)

^c NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LIPOPROTEIN A;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CONFERENCE PAPER; CORONARY ARTERY DISEASE; GENE CONTROL; HIGH RISK POPULATION; IMMUNOASSAY; LIPOPROTEIN BLOOD LEVEL; RISK FACTOR;

ANIMALS; CARDIOVASCULAR DISEASES; HUMANS; IMMUNOASSAY; LIPOPROTEIN(A); NATIONAL INSTITUTES OF HEALTH (U.S.); RISK FACTORS; UNITED STATES;

EID: 0242331117     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2003.023689     Document Type: Conference Paper

References (86)

1. Berg K. A new serum type system in man: the Lp system. Acta Pathol Microbiol Scand 1963;59:362-82.
2. Utermann G, Menzel HJ, Kraft HG, Duba HC, Kemmler HG, Seitz C. Lp(a) glycoprotein phenotypes. Inheritance and relation to Lp(a)-lipoprotein concentrations in plasma. J Clin Invest 1987;80:458-65.
3. Marcovina SM, Koschinsky ML. A critical evaluation of the role of Lp(a) in cardiovascular disease: can Lp(a) be useful in risk assessment? Semin Vasc Med 2002;2:335-44.
4. Rath M, Niendorf A, Reblin T, Dietel M, Krebber HJ, Beisiegel U. Detection and quantification of lipoprotein(a) in the arterial wall of 107 coronary bypass patients. Arteriosclerosis 1989;9:579-92.
5. Cushing GL, Gaubatz JW, Nava ML, Burdick BJ, Bocan TM, Guyton JR, et al. Quantitation and localization of apolipoproteins [a] and B in coronary artery bypass vein grafts resected at re-operation. Arteriosclerosis 1989;9:593-603.
6. Papagrigorakis E, Iliopoulos D, Asimacopoulos PJ, Safi HJ, Weilbaecher DJ, Ghazzaly KG, et al. Lipoprotein(a) in plasma, arterial wall, and thrombus from patients with aortic aneurysm. Clin Genet 1997;52:262-71.
7. McLean JW, Tomlinson JE, Kuang W-J, Eaton DL, Chen EY, Fless GM, et al. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature 1987;330:132-7.
8. Lackner C, Cohen JC, Hobbs HH. Molecular definition of the extreme size polymorphism in apolipoprotein(a). Hum Mol Genet 1993;2:933-40.
9. van der Hoek YY, Wittekoek ME, Beisiegel U, Kastelein JJ, Koschinsky ML. The apolipoprotein(a) kringle IV repeats which differ from the major repeat kringle are present in variably sized isoforms. Hum Mol Genet 1993;2:361-6.
10. Gabel BR, Koschinsky ML. Sequences within apolipoprotein(a) kringle IV types 6-8 bind directly to low-density lipoprotein and mediate noncovalent association of apolipoprotein(a) with apolipoprotein B-100. Biochemistry 1998;37:7892-8.
11. Sangrar W, Marcovina SM, Koschinsky ML. Expression and characterization of apolipoprotein(a) kringle IV types 1, 2 and 10 in mammalian cells. Protein Eng 1994;7:723-31.
12. Kratzin H, Armstrong VW, Niehaus M, Hilschmann N, Seidel D. Structural relationship of an apolipoprotein (a) phenotype (570 kDa) to plasminogen: homologous kringle domains are linked by carbohydrate-rich regions. Biol Chem Hoppe Seyler 1987;368:1533-44.
13. Garner B, Merry AH, Royle L, Harvey DJ, Rudd PM, Thillet J. Structural elucidation of the N- and O-glycans of human apolipoprotein(a): role of o-glycans in conferring protease resistance. J Biol Chem 2001;276:22200-8.
14. Marcovina SM, Albers JJ, Wijsman E, Zhang ZH, Chapman NH, Kennedy H. Differences in Lp(a) concentrations and apo(a) polymorphs between black and white Americans. J Lipid Res 1996;37:2569-85.
15. Kraft HG, Menzel HJ, Hoppichler F, Vogel W, Utermann G. Changes of genetic apolipoprotein phenotypes caused by liver transplantation. Implications for apolipoprotein synthesis. J Clin Invest 1989;83:137-42.
16. White AL, Lanford RE. Cell surface assembly of lipoprotein(a) in primary cultures of baboon hepatocytes. J Biol Chem 1994;269:28716-23.
17. Morrisett JD, Gaubatz JW, Nava MN, Guyton JR, Hoffmann AS, Opekun AR, et al. Metabolism of apo(a) and apo B-100 in human lipoprotein(a). In: Catapano AL, Gotto AM Jr, Smith LC, Paoletti R, eds. Drugs affecting lipid metabolism. Dordrecht, The Netherlands: Kluwer Academic Publishers, 1993:161-7.
18. Su W, Campos H, Judge H, Walsh BW, Sacks FM. Metabolism of Apo(a) and ApoB100 of lipoprotein(a) in women: effect of post-menopausal estrogen replacement. J Clin Endocrinol Metab 1998;83:3267-76.
19. Krempler F, Kostner GM, Bolzano K, Sandhofer F. Turnover of lipoprotein (a) in man. J Clin Invest 1980;65:1483-90.
20. Rader DJ, Cain W, Ikewaki K, Talley G, Zech LA, Usher D, et al. The inverse association of plasma lipoprotein(a) concentrations with apolipoprotein(a) isoform size is not due to differences in Lp(a) catabolism but to differences in production rate. J Clin Invest 1994;93:2758-63.
21. White AL, Hixson JE, Rainwater DL, Lanford RE. Molecular basis for "null" lipoprotein(a) phenotypes and the influence of apoli poprotein(a) size on plasma lipoprotein(a) level in the baboon. J Biol Chem 1994;269:9060-6.
22. Brunner C, Kraft HG, Utermann G, Muller HJ. Cys4057 of apolipoprotein(a) is essential for lipoprotein(a) assembly. Proc Natl Acad Sci U S A 1993;90:11643-7.
23. Koschinsky ML, Cote GP, Gabel B, van der Hoek YY. Identification of the cysteine residue in apolipoprotein(a) that mediates extracellular coupling with apolipoprotein B-100. J Biol Chem 1993;268:19819-25.
24. Albers JJ, Kennedy H, Marcovina SM. Evidence that Lp(a) contains one molecule of apo(a) and one molecule of apo B: evaluation of amino acid analysis data. J Lipid Res 1996;37:192-6.
25. Ernst A, Helmhold M, Brunner C, Petho-Schramm A, Armstrong VW, Muller HJ. Identification of two functionally distinct lysine-binding sites in kringle 37 and in kringles 32-36 of human apolipoprotein(a). J Biol Chem 1995;270:6227-34.
26. Trieu VN, McConathy WJ. A two-step model for lipoprotein(a) formation. J Biol Chem 1995;270:15471-4.
27. Gabel BR, May LF, Marcovina SM, Koschinsky ML. Lipoprotein(a) assembly. Quantitative assessment of the role of apo(a) kringle IV types 2-10 in particle formation. Arterioscler Thromb Vasc Biol 1996;16:1559-67.
28. Becker L, McLeod RS, Marcovina SM, Yao Z, Koschinsky ML. Identification of a critical lysine residue in apolipoprotein B-100 that mediates noncovalent interaction with apolipoprotein(a). J Biol Chem 2001;276:36155-62.
29. Cheesman EJ, Sharp RJ, Zlot CH, Liu CY, Taylor S, Marcovina SM, et al. An analysis of the interaction between mouse apolipoprotein B100 and apolipoprotein(a). J Biol Chem 2000;275:28195-200.
30. Sharp RJ, Perugini MA, Marcovina SM, McCormick SP. A synthetic peptide that inhibits lipoprotein(a) assembly. Arterioscler Thromb Vasc Biol 2003;23:502-7.
31. Frank S, Durovic S, Kostner K, Kostner GM. Inhibitors for the in vitro assembly of Lp(a). Arterioscler Thromb Vasc Biol 1995;15:1774-80.
32. Becker L, Webb BA, Chitayat S, Nesheim ME, Koschinsky ML. A ligand-induced conformational change in apolipoprotein(a) enhances covalent Lp(a) formation. J Biol Chem 2003;278:14074-81.
33. Kostner KM, Maurer G, Huber K, Stefenelli T, Dieplinger H, Steyrer E, et al. Urinary excretion of apo(a) fragments. Role in apo(a) catabolism. Arterioscler Thromb Vasc Biol 1996;16:905-11.
34. Koschinsky ML, Marcovina SM. Lipoprotein(a): structural implications for pathophysiology. Int J Clin Lab Res 1997;27:14-23.
35. Gaubatz JW, Hoogeveen RC, Hoffman AS, Ghazzaly KG, Pownall HJ, Guevara J Jr, et al. Isolation, quantitation, and characterization of a stable complex formed by Lp[a] binding to triglyceride-rich lipoproteins. J Lipid Res 2001;42:2058-68.
36. Utermann G, Duba C, Menzel HJ. Genetics of the quantitative Lp(a) lipoprotein trait. II. Inheritance of Lp(a) glycoprotein phenotypes. Hum Genet 1988;78:47-50.
37. Boerwinkle E, Leffert CC, Lin J, Lackner C, Chiesa G, Hobbs HH. Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations. J Clin Invest 1992;90:52-60.
38. Scholz M, Kraft HG, Lingenhel A, Delport R, Vorster EH, Bickeboller H, et al. Genetic control of lipoprotein(a) concentrations is different in Africans and Caucasians. Eur J Hum Genet 1999;7:169-78.
39. Trommsdorff M, Kochl S, Lingenhel A, Kronenberg F, Delport R, Vermaak H, et al. A pentanucleotide repeat polymorphism in the 5′ control region of the apolipoprotein(a) gene is associated with lipoprotein(a) plasma concentrations in Caucasians. J Clin Invest 1995;96:150-7.
40. Kraft HG, Windegger M, Menzel HJ, Utermann G. Significant impact of the +93 C/T polymorphism in the apolipoprotein(a) gene on Lp(a) concentrations in Africans but not in Caucasians: confounding effect of linkage disequilibrium. Hum Mol Genet 1998;7:257-64.
41. Kronenberg F, Kronenberg MF, Kiechl S, Trenkwalder E, Santer P, Oberhollenzer F, et al. Role of lipoprotein(a) and apolipoprotein(a) phenotype in atherogenesis. Prospective results from the Bruneck study. Circulation 1999;100:1154-60.
42. Lawn RM, Boonmark NW, Schwartz K, Lindahl GE, Wade DP, Byrne CD, et al. The recurring evolution of lipoprotein(a). Insights from cloning of hedgehog apolipoprotein(a). J Biol Chem 1995;270:24004-9.
43. Boffelli D, McAuliffe J, Ovcharenko D, Lewis KD, Ovcharenko I, Pachter L, et al. Phylogenetic shadowing of primate sequences to find functional regions of the human genome. Science 2003;299:1391-4.
44. Wade DP, Lindahl GE, Lawn RM. Apolipoprotein(a) gene transcription is regulated by liver-enriched trans-acting factor hepatocyte nuclear factor 1α. J Biol Chem 1994;269:19757-65.
45. Lawn RM. How often has Lp(a) evolved? Clin Genet 1996;49:167-74.
46. Lawn RM, Wade DP, Hammer RE, Chiesa G, Verstuyft JG, Rubin EM. Atherogenesis in transgenic mice expressing human apolipoprotein(a). Nature 1992;360:670-2.
47. Callow MJ, Verstuyft J, Tangirala R, Palinski W, Rubin EM. Atherogenesis in transgenic mice with human apolipoprotein B and lipoprotein (a). J Clin Invest 1995;96:1639-46.
48. Mancini FP, Newland DL, Mooser V, Murata J, Marcovina S, Young SG, et al. Relative contributions of apolipoprotein(a) and apolipoprotein-B to the development of fatty lesions in the proximal aorta of mice. Arterioscler Thromb Vasc Biol 1995;15:1911-6.
49. Sanan DA, Newland DL, Tao R, Marcovina S, Wang J, Mooser V, et al. Low density lipoprotein receptor-negative mice expressing human apolipoprotein B-100 develop complex atherosclerotic lesions on a chow diet: no accentuation by apolipoprotein(a). Proc Natl Acad Sci U S A 1998;95:4544-9.
50. Berg K, Svindland A, Smith AJ, Lawn RM, Djurovic S, Alestrom A, et al. Spontaneous atherosclerosis in the proximal aorta of LPA transgenic mice on a normal diet. Atherosclerosis 2002;163:99-104.
51. Fan J, Shimoyamada H, Sun H, Marcovina S, Honda K, Watanabe T. Transgenic rabbits expressing human apolipoprotein(a) develop more extensive atherosclerotic lesions in response to a cholesterol-rich diet. Arterioscler Thromb Vasc Biol 2001;21:88-94.
52. Sun H, Unoki H, Wang X, Liang J, Ichikawa T, Arai Y, et al. Lipoprotein(a) enhances advanced atherosclerosis and vascular calcification in WHHL transgenic rabbits expressing human apolipoprotein(a). J Biol Chem 2002;277:47486-92.
53. Watanabe Y. Serial inbreeding of rabbits with hereditary hyperlipidemia (WHHL-rabbit). Atherosclerosis 1980;36:261-8.
54. Marcovina SM, Albers JJ, Gabel B, Koschinsky ML, Gaur VP. Effect of the number of apolipoprotein(a) kringle 4 domains on immunochemical measurements of lipoprotein(a). Clin Chem 1995;41:246-55.
55. Edelstein C, Hinman J, Marcovina S, Scanu AM. Properties of human free apolipoprotein(a) and lipoprotein(a) after either freezing or lyophilization in the presence and absence of cryopreservatives. Anal Biochem 2001;288:201-8.
56. Marcovina SM, Albers JJ, Scanu AM, Kennedy H, Giaculli F, Berg K, et al. Use of a reference material proposed by the International Federation of Clinical Chemistry and Laboratory Medicine to evaluate analytical methods for the determination of plasma lipoprotein(a). Clin Chem 2000;46:1956-67.
57. Marcovina SM, Zhang ZH, Gaur VP, Albers JJ. Identification of 34 apolipoprotein(a) isoforms: differential expression of apolipoprotein(a) alleles between American blacks and whites. Biochem Biophys Res Commun 1993;191:1192-6.
58. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
59. Danesh J, Collins R, Peto R. Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. Circulation 2000;102:1082-5.
60. Sharrett AR, Ballantyne CM, Coady SA, Heiss G, Sorlie PD, Catellier D, et al. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation 2001;104:1108-13.
61. Glader CA, Birgander LS, Stenlund H, Dahlen GH. Is lipoprotein(a) a predictor for survival in patients with established coronary artery disease? Results from a prospective patient cohort study in northern Sweden. J Intern Med 2002;252:27-35.
62. Maher VM, Brown BG, Marcovina SM, Hillger LA, Zhao XQ, Albers JJ. Effects of lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein(a). JAMA 1995;274:1771-4.
63. Luc G, Bard JM, Arveiler D, Ferrieres J, Evans A, Amouyel P, et al. Lipoprotein (a) as a predictor of coronary heart disease: the PRIME Study. Atherosclerosis 2002;163:377-84.
64. Cantin B, Gagnon F, Moorjani S, Despres JP, Lamarche B, Lupien PJ, et al. Is lipoprotein(a) an independent risk factor for ischemic heart disease in men? The Quebec Cardiovascular Study. J Am Coll Cardiol 1998;31:519-25.
65. von Eckardstein A, Schulte H, Cullen P, Assmann G. Lipoprotein(a) further increases the risk of coronary events in men with high global cardiovascular risk. J Am Coll Cardiol 2001;37:434-9.
66. Nowak-Gottl U, Strater R, Heinecke A, Junker R, Koch HG, Schuierer G, et al. Lipoprotein (a) and genetic polymorphisms of clotting factor. V, prothrombin, and methylenetetrahydrofolate reductase are risk factors of spontaneous ischemic stroke in childhood. Blood 1999;94:3678-82.
67. Strater R, Becker S, von Eckardstein A, Heinecke A, Gutsche S, Junker R, et al. Prospective assessment of risk factors for recurrent stroke during childhood - a 5-year follow-up study. Lancet 2002;360:1540-5.
68. Nowak-Gottl U, Schobess R, Kurnik K, Schwabe D, Fleischhack G, Junker R. Elevated lipoprotein(a) concentration is an independent risk factor of venous thromboembolism. Blood 2002;99:3476-7,author reply 3477-8.
69. von Depka M, Nowak-Gottl U, Eisert R, Dieterich C, Barthels M, Scharrer I, et al. Increased lipoprotein (a) levels as an independent risk factor for venous thromboembolism. Blood 2000;96:3364-8.
70. Nowak-Gottl U, Junker R, Kreuz W, von Eckardstein A, Kosch A, Nohe N, et al. Risk of recurrent venous thrombosis in children with combined prothrombotic risk factors. Blood 2001;97:858-62.
71. Marcovina SM, Koschinsky ML. Lipoprotein(a): structure, measurement and clinical significance. In: Rifai N, Warnick GR, Dominiczak MH, eds. Handbook of lipoprotein testing, 2nd ed. Washington, DC: AACC Press, 2000:345-85.
72. Armstrong VW, Schleef J, Thiery J, Muche R, Schuff-Werner P, Eisenhauer T, et al. Effect of HELP-LDL-apheresis on serum concentrations of human lipoprotein(a): kinetic analysis of the post-treatment return to baseline levels. Eur J Clin Invest 1989; 19:235-40.
73. Pokrovsky SN, Adamova I, Afanasieva OY, Benevolenskaya GF. Immunosorbent for selective removal of lipoprotein(a) from human plasma: in vitro study. Artif Organs 1991;15:136-40.
74. Crouse JR 3rd. New developments in the use of niacin for treatment of hyperlipidemia: new considerations in the use of an old drug. Coron Artery Dis 1996;7:321-6.
75. Sirtori CR, Calabresi L, Ferrara S, Pazzucconi F, Bondioli A, Baldassarre D, et al. L-Carnitine reduces plasma lipoprotein(a) levels in patients with hyper Lp(a). Nutr Metab Cardiovasc Dis 2000;10:247-51.
76. Dalessandri KM. Reduction of lipoprotein(a) in postmenopausal women. Arch Intern Med 2001;161:772-3.
77. Shewmon DA, Stock JL, Rosen CJ, Heiniluoma KM, Hogue MM, Morrison A, et al. Tamoxifen and estrogen lower circulating lipoprotein(a) concentrations in healthy postmenopausal women. Arterioscler Thromb 1994;14:1586-93.
78. Plenge JK, Hernandez TL, Weil KM, Poirier P, Grunwald GK, Marcovina SM, et al. Simvastatin lowers C-reactive protein within 14 days: an effect independent of low-density lipoprotein cholesterol reduction. Circulation 2002;106:1447-52.
79. Dujovne CA, Harris WS, Altman R, Overhiser RW, Black DM. Effect of atorvastatin on hemorheologic-hemostatic parameters and serum fibrinogen levels in hyperlipidemic patients. Am J Cardiol 2000;85:350-3.
80. Cobbaert C, Jukema JW, Zwinderman AH, Withagen AJ, Lindemans J, Bruschke AV. Modulation of lipoprotein(a) atherogenicity by high density lipoprotein cholesterol levels in middle-aged men with symptomatic coronary artery disease and normal to moderately elevated serum cholesterol. Regression Growth Evaluation Statin Study (REGRESS) Study Group. J Am Coll Cardiol 1997;30:1491-9.
81. Duriez P, Dallongeville J, Fruchart JC. Lipoprotein(a) as a marker for coronary heart disease. Br J Clin Pract 1996;77A:54-61.
82. Gonbert S, Malinsky S, Sposito AC, Laouenan H, Doucet C, Chapman MJ, et al. Atorvastatin lowers lipoprotein(a) but not apolipoprotein(a) fragment levels in hypercholesterolemic subjects at high cardiovascular risk. Atherosclerosis 2002;164:305-11.
83. Akaike M, Azuma H, Kagawa A, Matsumoto K, Hayashi I, Tamura K, et al. Effect of aspirin treatment on serum concentrations of lipoprotein(a) in patients with atherosclerotic diseases. Clin Chem 2002;48:1454-9.
84. Kiortsis DN, Tzotzas T, Giral P, Bruckert E, Beucler I, Valsamides S, et al. Changes in lipoprotein(a) levels and hormonal correlations during a weight reduction program. Nutr Metab Cardiovasc Dis 2001;11:153-7.
85. Jenkins DJ, Kendall CW, Marchie A, Parker TL, Connelly PW, Qian W, et al. Dose response of almonds on coronary heart disease risk factors: blood lipids, oxidized low-density lipoproteins, lipoprotein(a), homocysteine, and pulmonary nitric oxide: a randomized, controlled, crossover trial. Circulation 2002;106:1327-32.
86. Ginsberg HN, Kris-Etherton P, Dennis B, Elmer PJ, Ershow A, Lefevre M, et al. Effects of reducing dietary saturated fatty acids on plasma lipids and lipoproteins in healthy subjects: the DELTA Study, protocol 1. Arterioscler Thromb Vasc Biol 1998;18:441-9.